A Phase 2 interventional study of Pridopidine and Placebo in Parkinson Disease, sponsored by Prilenia. Terminated at 33 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by Prilenia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 804th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2019, is one of 234 in phase 2, and was the 962nd registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 105 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Prilenia has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
138 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 138 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs. placebo for the treatment of Levodopa Induced Dyskinesia (LID) in patients with Parkinson Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1 (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
Drug: Pridopidine · Drug: Placebo
Dose 2 for (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
Drug: Pridopidine
Matching placebo (oral capsule) for 16 weeks
Drug: Placebo
Oral capsule
Oral capsule
Change From Baseline in Levodopa-induced Dyskinesia as Measured by UDysRS Score
Mean change from baseline (BL) in the sum of Parts 1, 3 and 4 of the Unified Dyskinesia Rating Scale (UdysRS), in the ON state. The UDysRS comprises 2 primary sections i.e. Historical \[Part 1 (ON-Dyskinesia) and Part 2 (OFF-Dystonia)\] and Objective \[Part 3 (Impairment) and Part 4 (Disability)\] assessment. ON-Dyskinesia are choreic and dystonic movements that occur when the Parkinson's disease (PD) medicine is working. Lower UDysRS values mean better patient outcome i.e. less dyskinesia. The UDysRS score for this study is calculated as sum of the parts, with scores of 0-44 for Part 1, 0-28 for Part 3 and 0-16 for Part 4.
Time frame: Baseline; Visit 7 (at Week 16) planned. Since the study was terminated early due to the COVID-19 pandemic, analysis of the primary endpoint was done at Visit 5 (Week 8/10) in those patients who were on study drug at this visit.
| Milestone | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo |
|---|---|---|---|
| Started | 7 | 8 | 8 |
| Treatment group based on maximal possible highest dose received (used for analysis) | 12 | 3 | 8 |
| Completed | 3 | 3 | 4 |
| Not completed | 4 | 5 | 4 |
| Withdrew: Adverse event | 3 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
| Withdrew: Not further specified | 0 | 0 | 1 |
Mean change from baseline (BL) in the sum of Parts 1, 3 and 4 of the Unified Dyskinesia Rating Scale (UdysRS), in the ON state. The UDysRS comprises 2 primary sections i.e. Historical \[Part 1 (ON-Dyskinesia) and Part 2 (OFF-Dystonia)\] and Objective \[Part 3 (Impairment) and Part 4 (Disability)\] assessment. ON-Dyskinesia are choreic and dystonic movements that occur when the Parkinson's disease (PD) medicine is working. Lower UDysRS values mean better patient outcome i.e. less dyskinesia. The UDysRS score for this study is calculated as sum of the parts, with scores of 0-44 for Part 1, 0-28 for Part 3 and 0-16 for Part 4.
| score on a scale | Pridopidine Total | Placebo |
|---|---|---|
| Baseline | 32.0 ± 10.44 | 35.9 ± 6.44 |
| Visit 5 | 14.7 ± 5.13 | 26.1 ± 11.02 |
| Change from baseline at Visit 5 | -17.3 ± 6.03 | -9.7 ± 9.43 |
Collected over From screening onwards, through to Week 18 (planned); this included 2 weeks' safety follow-up after treatment completion. The study was discontinued early due to the COVID-19 pandemic. Actual exposure (mean treatment duration) was 38 days in all patients receiving pridopidine and 93 days in all patients receiving placebo.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pridopidine 100 mg BID | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Pridopidine 150 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Placebo | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Event | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo |
|---|---|---|---|
| DiverticulitisInfections and infestations | 0/12 | 0/3 | 1/8 |
| Event | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo |
|---|---|---|---|
| Dry eyeEye disorders | 1/12 | 1/3 | 0/8 |
| Dry mouthGastrointestinal disorders | 3/12 | 1/3 | 0/8 |
| FatigueGeneral disorders | 3/12 | 1/3 | 1/8 |
| Oedema peripheralGeneral disorders | 0/12 | 1/3 | 0/8 |
| Temperature intoleranceGeneral disorders | 0/12 | 1/3 | 0/8 |
| NasopharyngitisInfections and infestations | 1/12 | 1/3 | 0/8 |
| FallInjury, poisoning and procedural complications | 0/12 | 1/3 | 0/8 |
| Bacterial test positiveInvestigations | 0/12 | 1/3 | 0/8 |
| Protein urine presentInvestigations | 0/12 | 1/3 | 0/8 |
| Weight decreasedInvestigations | 0/12 | 1/3 | 0/8 |
A total of 8 patients were randomized to pridopidine 150 mg BID. Of these, 5 patients discontinued study drug during titration, i.e. did not reach the full maintenance dose. Therefore, they were analyzed under the 100 mg BID group. The 100 mg BID group included patients who received any dose between 75 mg QD and 100 mg BID.
| Age, Continuous(years) | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 69.0 ± 7.5 | 61.3 ± 12.7 | 64.0 ± 9.7 | 66.3 ± 9.0 |
| Sex: Female, Male(Participants) | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 7 | 1 | 5 | 13 |
| Male | 5 | 2 | 3 | 10 |
| Race (NIH/OMB)(Participants) | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 11 | 3 | 5 | 19 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Pridopidine 100 mg BID | Pridopidine 150 mg BID | Placebo | Total |
|---|---|---|---|---|
| United States | 12 | 3 | 8 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Jul 2020, 14 months.
Results were first posted in Jul 2022, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia